Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

被引：0
|
作者：
Mezquita, L. [1 ]
Remon, J. [1 ]
Nicotra, C. [2 ]
Noerholm, M. [3 ]
Brinkmann, K. [3 ]
Planchard, D. [4 ]
Jovelet, C. [5 ]
Auclin, E. [6 ]
Flinspach, C. [3 ]
Hurley, J. [3 ]
Skog, J. [7 ]
Gazzah, A. [2 ]
Caramella, C. [8 ]
Adam, J. [9 ]
Lacroix, L. [5 ]
Auger, N. [9 ]
Friboulet, L. [10 ]
Soria, J. [11 ,12 ]
Besse, B. [1 ]
机构：
[1] Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Gustave Roussy, Drug Dev Dept, Villejuif, France
[3] Exosome Diagnost GmbH, Martinsried, Germany
[4] Gustave Roussy, Med Oncol, Villejuif, France
[5] Gustave Roussy, Translat Res Lab, Villejuif, France
[6] Hop Georges Pompidou, Paris, France
[7] Exosome Diagnost Inc, Waltham, MA USA
[8] Gustave Roussy, Radiol Dept, Villejuif, France
[9] Gustave Roussy Canc Campus, Dept Med Biol & Pathol, Villejuif, France
[10] Gustave Roussy, Inserm U981 Lab, Villejuif, France
[11] Gustave Roussy Canc Campus, Drug Dev Dept, Paris, France
[12] Gustave Roussy Canc Campus, Inserm U981 Lab, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.03-013
引用
收藏
页码：S1954 / S1955
页数：2
相关论文
共 50 条
  • [31] Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    Shaw, A. T.
    Varghese, A. M.
    Solomon, B. J.
    Costa, D. B.
    Novello, S.
    Mino-Kenudson, M.
    Awad, M. M.
    Engelman, J. A.
    Riely, G. J.
    Monica, V.
    Yeap, B. Y.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 59 - 66
  • [32] Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan
    Goto, Y.
    Yamamoto, N.
    Masters, E.
    Kikkawa, H.
    Mardekian, J.
    Wiltshire, R.
    Togo, K.
    Ma, H.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S878 - S879
  • [33] Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
    Leal, T.
    Wakelee, H.
    Reckamp, K.
    Waqar, S.
    Patel, S.
    Blumenschein, G.
    Neal, J.
    Harrow, K.
    Holzhausen, A.
    Liang, C.
    Dukart, G.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S156 - S156
  • [34] Catechol estrogen profiles of patients with EGFR- and ALK-positive non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Treat, Joseph
    Krzizike, Daniel D.
    Zawislak, Carolyn L.
    Vanderveer, Lisa
    Eidbo, Sarah
    Ross, Eric A.
    Edelman, Martin J.
    Andrews, Andrew J.
    Clapper, Margie L.
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Impact of Patient TKI Copayments on Insurance Expenditure in Advanced EGFR or ALK Positive Non-Small Cell Lung Cancer (NSCLC)
    Goulart, B. Haddock Lobo
    Chennupati, S.
    Egan, K.
    Fedorenko, C.
    Ramsey, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S599 - S599
  • [36] GENOMIC ALTERATIONS IN ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES
    Eichholz, Jordan
    Miao, Emily
    Lebow, Emily
    Walch, Henry
    Flynn, Jessica
    Zhang, Zhigang
    Hubbeling, Harper
    Beal, Kathryn
    Moss, Nelson
    Yu, Kenny
    Yang, Jonathan
    Meng, Alicia
    Kelly, Daniel
    Boerner, Thomas
    Gomez, Daniel
    Rimner, Andreas
    Schultz, Nikolaus
    Drilon, Alexander
    Imber, Brandon
    Pike, Luke
    NEURO-ONCOLOGY, 2022, 24 : 3 - 3
  • [37] Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Shi, Yuankai
    De Pas, Tommaso Martino
    Yang, Pan-Chyr
    Riely, Gregory J.
    Crino, Lucio
    Evans, Tracey L.
    Liu, Xiaoqing
    Han, Ji-Youn
    Salgia, Ravi
    Moro-Sibilot, Denis
    Ou, Sai-Hong Ignatius
    Gettinger, Scott N.
    Wu, Yi Long
    Lanzalone, Silvana
    Polli, Anna
    Iyer, Shrividya
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Nishio, Makoto
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Solomon, Benjamin J.
    Shaw, Alice T.
    Hashigaki, Satoshi
    Ohki, Emiko
    Usari, Tiziana
    Paolini, Jolanda
    Polli, Anna
    Wilner, Keith D.
    Mok, Tony
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
  • [39] Results of A Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Riely, G. J.
    Evans, T. L.
    Salgia, R.
    Ou, S. I.
    Gettinger, S. N.
    Otterson, G. A.
    Lanzalone, S.
    Polli, A.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204
  • [40] Evaluation of Texture Analysis Parameters in EGFR Mutated or ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
    Bluthgen, Maria V.
    Caramella, Caroline
    Rosellini, Silvia
    Leduc, Charlotte
    Facchinetti, Francesco
    Haspinger, Eva
    Ferte, Charles
    Michiels, Stefan
    Soria, Jean C.
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S703 - S703
12345